Eli Lilly monoclonal antibodies less effective against Covid variant?
Why the U.S. Department of Health and Human Services has restricted the use of Eli Lilly's monoclonal antibodies in California, Arizona and Nevada
Eli Lilly's monoclonal antibodies may be ineffective against a new Covid-19 variant, widespread in California. And that's why the US Department of Health and Human Services has restricted its use in three US states. All the details.
THE CAL.20C VARIANT
After the English, South African and Brazilian variants of Covid-19, a new variant has emerged in California, more transmissible and associated with a higher mortality. It's called CAL.20C , it was first detected in October 2020 and appears to be even more resistant to current vaccines.
CALIFORNIAN VARIANT RESISTANTS ELI LILLY ANTIBODIES
The variant also appears to be resistant to the monoclonal antibody-based therapy developed by Eli Lilly and authorized by the FDA for emergency use in November 2020.
LIMITATIONS OF USE
And it is in the name of this resistance that the US Department of Health and Human Services, Reuters writes, has decided to limit its use of the antibody bamlanivimab in three different US states, California, Arizona and Nevada, where the variant is predominant.
ELI LILLY: STUDIES CONTINUE
Meanwhile, clinical studies are continuing. And just in recent days, the American company, Eli Lilly, announced that its therapy, which includes a combination of monoclonals, has reduced the risk of hospitalization and death by 87% in high-risk Covid-19 patients in a study.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/anticorpi-monoclonali-eli-lylli-meno-efficaci-contro-nuova-variante/ on Thu, 25 Mar 2021 14:08:24 +0000.